S
Investor profile
Investment firm
S has backed 8 European tech companies across 12 funding rounds between 2004 and 2018, joining rounds totalling €477M. Most active in Healthtech and HRtech. Data as of Nov 2026.
Deals
12
distinct rounds
Companies
8
backed
Active span
2004–2018
15 yrs
Total round €
€477M
sum of rounds joined
Deals by year
distinct rounds / yearS — deals by year — interactive chart.
Data table
| S — deals by year | |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
Top sectors
by dealsS — top sectors — interactive chart.
Data table
| S — top sectors | |
|---|---|
| Healthtech | 9 |
| HRtech | 2 |
| Fashion | 1 |
Stages
by dealsS — stages — interactive chart.
Data table
| S — stages | |
|---|---|
| Series A | 3 |
| Growth/Late | 2 |
| Series C | 2 |
| Series D+ | 2 |
| Other | 2 |
| Debt | 1 |
Countries
by dealsS — countries — interactive chart.
Data table
| S — countries | |
|---|---|
| Denmark | 7 |
| UK | 3 |
| Germany | 1 |
| Netherlands | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Novo A9
- Essex Woodlands Health Ventures3
- Advent Venture Partners2
- Novartis Venture Fund2
- Aisling Capital1
- Brace Pharma1
- Brightfolk A1
- Gilde Healthcare1
- Growth Foundation1
- Inter-Invest A1
- Life Sciences Partners1
- Merifin Capital1
- Moment A1
- New Enterprise Associates1
- Roos Group AB1
- Sectoral Asset Management1
- Sofinnova Partners1
- Sunstone Capital1
- Takeda Ventures1
- Wellington Partners1
- Zobito1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Symphogen | Denmark | 5 | €249M |
| Adaptimmune | UK | 1 | €79M |
| Merus | Netherlands | 1 | €73M |
| F2G | UK | 1 | €55M |
| NeRRe Therapeutics | UK | 1 | €14M |
| Ivy & Oak | Germany | 1 | €5.0M |
| Learning Bank | Denmark | 1 | €1.9M |
| Chabber | Denmark | 1 | €134k |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Symphogen | Series D+ | €100M | 2011-02 |
| Adaptimmune | Series A | €79M | 2014-09 |
| Merus | Series C | €73M | 2015-08 |
| Symphogen | Debt | €68M | 2015-10 |
| F2G | Growth/Late | €55M | 2016-06 |
| Symphogen | Growth/Late | €41M | 2013-05 |
| Symphogen | Series D+ | €21M | 2006-01 |
| Symphogen | Series C | €20M | 2004-11 |
| NeRRe Therapeutics | Series A | €14M | 2012-12 |
| Ivy & Oak | Series A | €5.0M | 2018-07 |